NCT04833582 is a Phase 1 clinical trial of Azenosertib in Osteosarcoma, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Who is sponsoring NCT04833582?

NCT04833582 is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

What drugs are being tested in NCT04833582?

Interventions in NCT04833582: Azenosertib, Gemcitabine.

What condition does NCT04833582 study?

NCT04833582 studies Osteosarcoma.

Is NCT04833582 still recruiting?

NCT04833582 is currently completed. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT04833582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed Phase 1 Last updated 3 April 2026

What this trial tests

Phase 1 trial testing Azenosertib in Osteosarcoma in 31 participants. Completed in 30 March 2024.

Timeline

1 August 2021

Primary endpoint
30 August 2023

30 March 2024

Quick facts

Lead sponsor	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 August 2021
Primary completion	30 August 2023
Estimated completion	30 March 2024
Sites	17 locations across France, United States

Drugs / interventions tested

Azenosertib — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Osteosarcoma — all drugs for Osteosarcoma →

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc — full company profile →

Who can join

12 and older, any sex, with Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1/2 study of azenosertib (ZN-c3) in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A new wave of innovations within the DNA damage response.
Li Q, Qian W, Zhang Y, Hu L, et al · · 2023 · cited 85× · PMID 37679326 · DOI 10.1038/s41392-023-01548-8
Targeted therapy for osteosarcoma: a review.
Li S, Zhang H, Liu J, Shang G. · · 2023 · cited 66× · PMID 36807762 · DOI 10.1007/s00432-023-04614-4
Targeting the DNA damage response for cancer therapy.
Curtin NJ. · · 2023 · cited 30× · PMID 36606678 · DOI 10.1042/bst20220681
Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?
Kim C, Davis LE, Albert CM, Samuels B, et al · · 2023 · cited 29× · PMID 37894411 · DOI 10.3390/cancers15205044
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli VJ, Yadav P, Suresh V, Jadav SS. · · 2023 · cited 18× · PMID 37323408 · DOI 10.1021/acsomega.3c01558
DNA repair and the contribution to chemotherapy resistance.
Nesic K, Parker P, Swisher EM, Krais JJ. · · 2025 · cited 16× · PMID 40420317 · DOI 10.1186/s13073-025-01488-8
Advancing cancer therapy: new frontiers in targeting DNA damage response.
Qian J, Liao G, Chen M, Peng RW, et al · · 2024 · cited 16× · PMID 39372203 · DOI 10.3389/fphar.2024.1474337
Targeting the DNA damage response in cancer.
Federica G, Michela C, Giovanna D. · · 2024 · cited 12× · PMID 39492835 · DOI 10.1002/mco2.788

Verify or expand the search:

Other trials of Azenosertib

Trials testing the same drug.

NCT06369155 — Azenosertib in Uterine Serous Carcinoma: Biomarker Study · Phase 2 · recruiting
NCT06364410 — Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi · Phase 1 · recruiting
NCT06351332 — ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC · Phase 1, PHASE2 · active not recruiting
NCT05198804 — A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer · Phase 1, PHASE2 · completed
NCT04814108 — A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma · Phase 2 · completed

Other recruiting trials for Osteosarcoma

Currently open trials in the same condition.

NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting

Other K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT05743036 — ZN-c3 in Adult Participants With Metastatic Colorectal Cancer · Phase 1 · terminated
NCT05128825 — A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary · Phase 2 · recruiting
NCT05198804 — A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer · Phase 1, PHASE2 · completed
NCT04814108 — A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma · Phase 2 · completed
NCT04516447 — A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04833582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing